The Duchenne muscular dystrophy drug developer's initial public offering could prove an exit ramp for Roche and Merck & Co.

US-based drug delivery platform developer Entrada Therapeutics has filed for an initial public offering (IPO) on the Nasdaq Global Market, marking a potential exit for pharmaceutical firms Merck & Co and Roche. Entrada has developed endosomal escape vehicle (EEV) technology that is designed to help medication reach inside both large and small cells to treat…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.